Abstract
Activation of angiogenesis is a necessary condition for tumor growth and metastatic dissemination of solid tumors. Numerous anti-angiogenic agents for the treatment of melanoma are currently in clinical trials or in development. A number of early-phase clinical trials have been completed and studies investigating combinations of targeted agents or combining treatment with chemotherapy are ongoing. The present review focuses on the most recent developments in the field of angiogenesis targeting in melanoma and provides a brief overview of available clinical data and future directions.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.